Loading...

Chloe Atreya, MD

TitleAssistant Professor
SchoolUCSF School of Medicine
DepartmentMedicine
Address550 16TH St., 6th Fl
San Francisco CA 94158
Phone415-353-9931
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale UniversityM.D.2005School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    Targeting of Aberrant Signaling in Patient-Derived Colorectal Cancer Models
    NIH K08CA175153Sep 15, 2013 - Aug 31, 2018
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Websites
    Collapse Clinical Trials
    Collapse Global Health
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Atreya CE, Venook AP. Role of Biologics in Colon Cancer: Still Not Clear. J Oncol Pract. 2016 Dec; 12(12):1229-1230. PMID: 27943687.
      View in: PubMed
    2. Atreya C, Greene C, McWhirter RM, Ikram NS, Allen IE, Van Loon K, Venook AP, Yeh BM, Behr SC. Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location. J Natl Compr Canc Netw. 2016 Dec; 14(12):1536-1543. PMID: 27956538.
      View in: PubMed
    3. Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May; 23(5):411-8. PMID: 27080472.
      View in: PubMed
    4. Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S. Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. J Clin Oncol. 2015 Dec 1; 33(34):4023-31. PMID: 26392102.
      View in: PubMed
    5. Zill OA, Greene C, Sebisanovic D, Siew LM, Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, Van Loon K, Ko AH, Tempero MA, Bivona TG, Munster PN, Talasaz A, Collisson EA. Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. Cancer Discov. 2015 Oct; 5(10):1040-8. PMID: 26109333; PMCID: PMC4592417.
    6. Atreya CE, Corcoran RB, Kopetz S. Expanded RAS: refining the patient population. J Clin Oncol. 2015 Mar 1; 33(7):682-5. PMID: 25584005; PMCID: PMC4334773 [Available on 03/01/16].
    7. Song EK, Tai W, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2015 Apr 15; 136(8):1967-75. PMID: 25242168; PMCID: PMC4323738 [Available on 04/15/16].
    8. Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM. Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res. 2013 Oct 15; 19(20):5777-87. PMID: 23983256; PMCID: PMC4122229.
    9. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013 Aug; 2(4):496-506. PMID: 24156022; PMCID: PMC3799284.
    10. Atreya C, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, and Warren RS. . Cancer Medicine. PTEN Expression is Consistent in Colorectal Cancer Primaries and Metastases and Associates with Patient Survival. 2013.
    11. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Oncogene. 2014 Mar 20; 33(12):1590-600. PMID: 23542178; PMCID: PMC3982880.
    12. Atreya C, Ostrem JM, and Kelley RK. Personalized Medicine in Oncology. KRAS and Colorectal Cancer: Shades of Gray. 2012; 6(1).
    13. Kelley RK, Atreya C, Venook AP, Febbo PG. Predictive biomarkers in advance of a companion drug: ahead of their time? J Natl Compr Canc Netw. 2012 Mar; 10(3):303-9. PMID: 22393192.
      View in: PubMed
    14. Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM. Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer. Invest New Drugs. 2012 Dec; 30(6):2219-25. PMID: 22270257.
      View in: PubMed
    Chloe's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _
    Back to TOP